Abstract
Background: The optimal isotretinoin dosing strategy for acne vulgaris remains debated, balancing efficacy against dose-dependent toxicity. Objective: To compare the efficacy, safety, and post-treatment outcomes of low-dose (≤0.5 mg/kg/day) versus conventional-dose (0.5–1.0 mg/kg/day) isotretinoin. Methods: We searched PubMed, Embase, CENTRAL, and Web of Science for randomized controlled trials (RCTs). The primary outcome was the change in Global Acne Grading System (GAGS) score at 24 weeks. Secondary outcomes included post-treatment worsening quantified as GAGS score deterioration, adverse events, and patient satisfaction. Certainty of evidence was assessed using GRADE. Results: Four trials (210 randomized; 202 analyzed) were included. At 24 weeks, the pooled mean difference favored neither regimen [MD = −1.87, 95% CI (−4.38, 0.64); p = 0.15; I² = 85.67%]. Heterogeneity was predominantly attributable to one trial that enrolled more severe cases and used adjunctive antibiotics/corticosteroids; excluding it reduced heterogeneity and maintained no significant difference under a random-effects model [MD = −0.92, 95% CI (−2.62, 0.77); p = 0.28; I² = 44.97%]. Post-treatment worsening did not differ overall and, in sensitivity analyses excluding the co-intervention trial, showed no statistically significant difference with no heterogeneity [MD = 0.10, 95% CI (−1.67, 1.86); p = 0.91; I² = 0%]. Low-dose regimens had higher patient satisfaction [SMD = 0.99, 95% CI (0.63, 1.34); p < 0.001] and better tolerability. Certainty of evidence was low for efficacy and moderate for safety and satisfaction (GRADE). Conclusion: In RCTs conducted predominantly in moderate acne and in contexts minimizing co-interventions, low-dose isotretinoin provides comparable 24-week efficacy to conventional dosing while offering superior tolerability and higher patient satisfaction. Conventional dosing may yield a modestly faster early response; however, the absolute differences were small and evidence in substantially more severe acne remains limited and context-dependent.
Introduction
Isotretinoin is the definitive treatment for severe acne, uniquely targeting all four pathogenic pathways of the disease. However, its use is often limited by dose-dependent "mucocutaneous toxicity," such as severe cheilitis, xerosis, and epistaxis. Traditional guidelines, established in the 1980s, recommend high daily doses (0.5–1.0 mg/kg) to reach a cumulative target of 120–150 mg/kg, a threshold believed to prevent relapse. For many patients with moderate acne, this approach can lead to significant overtreatment. This systematic review evaluates whether low-dose regimens (≤0.5 mg/kg/day) can provide comparable efficacy with improved tolerability and patient satisfaction.
Methods
The researchers conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing low-dose versus conventional-dose oral isotretinoin. The primary outcome was the change in the Global Acne Grading System (GAGS) score at 24 weeks. Secondary outcomes included patient satisfaction, adverse events, and post-treatment worsening (relapse). The study selection process, which identified four eligible RCTs, is summarized in the PRISMA flow diagram below.
Key Results
The analysis of 202 patients across four trials revealed several key insights:
- Efficacy Convergence: By week 24, there was no statistically significant difference in acne clearance between the low-dose and conventional-dose groups (Mean Difference = -1.87, p = 0.15). While higher doses may work faster initially, the outcomes converge over time.
- Superior Tolerability: Low-dose regimens dramatically reduced side effects. For instance, the incidence of epistaxis (nosebleeds) dropped from 18.8% to 0% in one representative trial.
- Higher Patient Satisfaction: Patients reported significantly higher satisfaction with low-dose therapy (Standardized Mean Difference = 0.99, p < 0.001), likely due to the improved side-effect profile.
- Relapse Rates: No significant difference in post-treatment worsening was observed between the groups during 6–12 months of follow-up (p = 0.91) when excluding trials with confounding co-interventions.
Discussion
These findings challenge the traditional "cumulative dose dogma," suggesting that clinical clearance and maintenance may be more critical than reaching an arbitrary milligram-per-kilogram target. A treatment that a patient can comfortably complete is often more effective in practice than a more intensive regimen that leads to early discontinuation.
However, the evidence for efficacy is currently rated as "low certainty" under the GRADE framework, partly due to the small number of RCTs and specific risks of bias identified in the included studies. Furthermore, as most participants had moderate acne, it remains unclear if these findings apply to the most severe, nodulocystic cases.
Conclusion
Low-dose isotretinoin offers a patient-centered alternative to conventional dosing, providing comparable 24-week efficacy with significantly better tolerability and higher satisfaction. For moderate acne, individualizing the dose to minimize toxicity while maintaining efficacy represents a more balanced clinical approach.
Summary updated